Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors. A COG Phase I Consortium Report (ADVL1312).

Cole KA, Pal S, Kudgus RA, Ijaz H, Liu X, Minard CG, Pawel BR, Maris JM, Haas-Kogan DA, Voss SD, Berg SL, Reid JM, Fox E, Weigel BJ.

Clin Cancer Res. 2019 Dec 19. doi: 10.1158/1078-0432.CCR-19-3470. [Epub ahead of print]

PMID:
31857431
2.

Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411).

Schafer ES, Rau RE, Berg SL, Liu X, Minard CG, Bishop AJR, Romero JC, Hicks MJ, Nelson MD Jr, Voss S, Reid JM, Fox E, Weigel BJ, Blaney SM.

Pediatr Blood Cancer. 2020 Feb;67(2):e28073. doi: 10.1002/pbc.28073. Epub 2019 Nov 14.

PMID:
31724813
3.

Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group.

Kopp LM, Malempati S, Krailo M, Gao Y, Buxton A, Weigel BJ, Hawthorne T, Crowley E, Moscow JA, Reid JM, Villalobos V, Randall RL, Gorlick R, Janeway KA.

Eur J Cancer. 2019 Nov;121:177-183. doi: 10.1016/j.ejca.2019.08.015. Epub 2019 Oct 3.

PMID:
31586757
4.

A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921).

Mossé YP, Fox E, Teachey DT, Reid JM, Safgren SL, Carol H, Lock RB, Houghton PJ, Smith MA, Hall D, Barkauskas DA, Krailo M, Voss SD, Berg SL, Blaney SM, Weigel BJ.

Clin Cancer Res. 2019 Jun 1;25(11):3229-3238. doi: 10.1158/1078-0432.CCR-18-2675. Epub 2019 Feb 18.

PMID:
30777875
5.

Identification of aggressive Gardner syndrome phenotype associated with a de novo APC variant, c.4666dup.

Kiessling P, Dowling E, Huang Y, Ho ML, Balakrishnan K, Weigel BJ, Highsmith WE Jr, Niu Z, Schimmenti LA.

Cold Spring Harb Mol Case Stud. 2019 Apr 1;5(2). pii: a003640. doi: 10.1101/mcs.a003640. Print 2019 Apr.

6.

A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315).

Geller JI, Fox E, Turpin BK, Goldstein SL, Liu X, Minard CG, Kudgus RA, Reid JM, Berg SL, Weigel BJ.

Cancer. 2018 Dec 1;124(23):4548-4555. doi: 10.1002/cncr.31725. Epub 2018 Nov 5. Erratum in: Cancer. 2019 Aug 15;125(16):2896.

7.

The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.

Malempati S, Weigel BJ, Chi YY, Tian J, Anderson JR, Parham DM, Teot LA, Rodeberg DA, Yock TI, Shulkin BL, Spunt SL, Meyer WH, Hawkins DS.

Cancer. 2019 Jan 15;125(2):290-297. doi: 10.1002/cncr.31770. Epub 2018 Oct 23.

8.

Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial.

Cole PD, McCarten KM, Pei Q, Spira M, Metzger ML, Drachtman RA, Horton TM, Bush R, Blaney SM, Weigel BJ, Kelly KM.

Lancet Oncol. 2018 Sep;19(9):1229-1238. doi: 10.1016/S1470-2045(18)30426-1. Epub 2018 Aug 16.

9.

A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314).

Schafer ES, Rau RE, Berg S, Liu X, Minard CG, D'Adamo D, Scott R, Reyderman L, Martinez G, Devarajan S, Reid JM, Fox E, Weigel BJ, Blaney SM.

Pediatr Blood Cancer. 2018 Aug;65(8):e27066. doi: 10.1002/pbc.27066. Epub 2018 May 2.

10.

A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group.

Chuk MK, Widemann BC, Minard CG, Liu X, Kim A, Bernhardt MB, Kudgus RA, Reid JM, Voss SD, Blaney S, Fox E, Weigel BJ.

Pediatr Blood Cancer. 2018 Aug;65(8):e27077. doi: 10.1002/pbc.27077. Epub 2018 Apr 25.

11.

Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213).

Norris RE, Fox E, Reid JM, Ralya A, Liu XW, Minard C, Weigel BJ.

Pediatr Blood Cancer. 2018 May;65(5):e26944. doi: 10.1002/pbc.26944. Epub 2018 Jan 2.

12.

Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.

London WB, Bagatell R, Weigel BJ, Fox E, Guo D, Van Ryn C, Naranjo A, Park JR.

Cancer. 2017 Dec 15;123(24):4914-4923. doi: 10.1002/cncr.30934. Epub 2017 Sep 8. Review.

13.

Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.

Mossé YP, Voss SD, Lim MS, Rolland D, Minard CG, Fox E, Adamson P, Wilner K, Blaney SM, Weigel BJ.

J Clin Oncol. 2017 Oct 1;35(28):3215-3221. doi: 10.1200/JCO.2017.73.4830. Epub 2017 Aug 8.

14.

Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.

Rudzinski ER, Anderson JR, Chi YY, Gastier-Foster JM, Astbury C, Barr FG, Skapek SX, Hawkins DS, Weigel BJ, Pappo A, Meyer WH, Arnold MA, Teot LA, Parham DM.

Pediatr Blood Cancer. 2017 Dec;64(12). doi: 10.1002/pbc.26645. Epub 2017 May 18.

15.

A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111).

Geller JI, Perentesis JP, Liu X, Minard CG, Kudgus RA, Reid JM, Fox E, Blaney SM, Weigel BJ.

Pediatr Blood Cancer. 2017 Nov;64(11). doi: 10.1002/pbc.26565. Epub 2017 Apr 27.

16.

A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114).

Rheingold SR, Tasian SK, Whitlock JA, Teachey DT, Borowitz MJ, Liu X, Minard CG, Fox E, Weigel BJ, Blaney SM.

Br J Haematol. 2017 May;177(3):467-474. doi: 10.1111/bjh.14569. Epub 2017 Mar 14.

17.

First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children's Oncology Group Phase 1/Pilot Consortium.

Balis FM, Thompson PA, Mosse YP, Blaney SM, Minard CG, Weigel BJ, Fox E.

Cancer Chemother Pharmacol. 2017 Jan;79(1):181-187. doi: 10.1007/s00280-016-3220-6. Epub 2016 Dec 28.

18.

Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.

Weigel BJ, Lyden E, Anderson JR, Meyer WH, Parham DM, Rodeberg DA, Michalski JM, Hawkins DS, Arndt CA.

J Clin Oncol. 2016 Jan 10;34(2):117-22. doi: 10.1200/JCO.2015.63.4048. Epub 2015 Oct 26.

19.

A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011).

Loh ML, Tasian SK, Rabin KR, Brown P, Magoon D, Reid JM, Chen X, Ahern CH, Weigel BJ, Blaney SM.

Pediatr Blood Cancer. 2015 Oct;62(10):1717-24. doi: 10.1002/pbc.25575. Epub 2015 May 13.

20.

A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report.

Kolb EA, Sampson V, Stabley D, Walter A, Sol-Church K, Cripe T, Hingorani P, Ahern CH, Weigel BJ, Zwiebel J, Blaney SM.

Pediatr Blood Cancer. 2015 May;62(5):751-8. doi: 10.1002/pbc.25464. Epub 2015 Feb 27.

21.

Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group.

Burke MJ, Ahern C, Weigel BJ, Poirier JT, Rudin CM, Chen Y, Cripe TP, Bernhardt MB, Blaney SM.

Pediatr Blood Cancer. 2015 May;62(5):743-50. doi: 10.1002/pbc.25269. Epub 2014 Oct 12.

22.

A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia.

Burke MJ, Lamba JK, Pounds S, Cao X, Ghodke-Puranik Y, Lindgren BR, Weigel BJ, Verneris MR, Miller JS.

Am J Hematol. 2014 Sep;89(9):889-95. doi: 10.1002/ajh.23778. Epub 2014 Jun 27.

23.

Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.

Bagatell R, Norris R, Ingle AM, Ahern C, Voss S, Fox E, Little AR, Weigel BJ, Adamson PC, Blaney S.

Pediatr Blood Cancer. 2014 May;61(5):833-9. doi: 10.1002/pbc.24874. Epub 2013 Nov 19.

24.

A phase I trial of imetelstat in children with refractory or recurrent solid tumors: a Children's Oncology Group Phase I Consortium Study (ADVL1112).

Thompson PA, Drissi R, Muscal JA, Panditharatna E, Fouladi M, Ingle AM, Ahern CH, Reid JM, Lin T, Weigel BJ, Blaney SM.

Clin Cancer Res. 2013 Dec 1;19(23):6578-84. doi: 10.1158/1078-0432.CCR-13-1117. Epub 2013 Oct 4.

25.

Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report.

Glade Bender JL, Lee A, Reid JM, Baruchel S, Roberts T, Voss SD, Wu B, Ahern CH, Ingle AM, Harris P, Weigel BJ, Blaney SM.

J Clin Oncol. 2013 Aug 20;31(24):3034-43. doi: 10.1200/JCO.2012.47.0914. Epub 2013 Jul 15.

26.

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

Mossé YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, Rolland D, Balis FM, Maris JM, Weigel BJ, Ingle AM, Ahern C, Adamson PC, Blaney SM.

Lancet Oncol. 2013 May;14(6):472-80. doi: 10.1016/S1470-2045(13)70095-0. Epub 2013 Apr 16.

27.

A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916).

Muscal JA, Thompson PA, Horton TM, Ingle AM, Ahern CH, McGovern RM, Reid JM, Ames MM, Espinoza-Delgado I, Weigel BJ, Blaney SM.

Pediatr Blood Cancer. 2013 Mar;60(3):390-5. doi: 10.1002/pbc.24271. Epub 2012 Aug 9.

28.

Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies.

Weigel BJ, Cooley S, DeFor T, Weisdorf DJ, Panoskaltsis-Mortari A, Chen W, Blazar BR, Miller JS.

Am J Hematol. 2012 Oct;87(10):953-6. doi: 10.1002/ajh.23280. Epub 2012 Jun 20.

29.

Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia.

Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH, Murphy WJ, Azuma M, Anderson AC, Kuchroo VK, Blazar BR.

Blood. 2011 Apr 28;117(17):4501-10. doi: 10.1182/blood-2010-10-310425. Epub 2011 Mar 8.

30.

Allogeneic hematopoietic cell transplantation outcomes for children with B-precursor acute lymphoblastic leukemia and early or late BM relapse.

Beck JC, Cao Q, Trotz B, Smith AR, Weigel BJ, Verneris MR, Burke MJ.

Bone Marrow Transplant. 2011 Jul;46(7):950-5. doi: 10.1038/bmt.2010.217. Epub 2010 Sep 20.

PMID:
20856210
31.

Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia.

Zhou Q, Munger ME, Highfill SL, Tolar J, Weigel BJ, Riddle M, Sharpe AH, Vallera DA, Azuma M, Levine BL, June CH, Murphy WJ, Munn DH, Blazar BR.

Blood. 2010 Oct 7;116(14):2484-93. doi: 10.1182/blood-2010-03-275446. Epub 2010 Jun 22.

32.

Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia.

Zhou Q, Bucher C, Munger ME, Highfill SL, Tolar J, Munn DH, Levine BL, Riddle M, June CH, Vallera DA, Weigel BJ, Blazar BR.

Blood. 2009 Oct 29;114(18):3793-802. doi: 10.1182/blood-2009-03-208181. Epub 2009 Sep 1.

33.

Cutaneous pseudolymphoma: an unusual presentation of a scalp mass.

Nnebe NV, Woon C, Haines S, Dayton V, Weigel BJ.

Pediatr Blood Cancer. 2009 Feb;52(2):283-5. doi: 10.1002/pbc.21767.

PMID:
18839432
34.

Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD).

Taylor PA, Ehrhardt MJ, Lees CJ, Tolar J, Weigel BJ, Panoskaltsis-Mortari A, Serody JS, Brinkmann V, Blazar BR.

Blood. 2007 Nov 1;110(9):3480-8. Epub 2007 Jul 2.

35.

A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study.

Weigel BJ, Blaney SM, Reid JM, Safgren SL, Bagatell R, Kersey J, Neglia JP, Ivy SP, Ingle AM, Whitesell L, Gilbertson RJ, Krailo M, Ames M, Adamson PC.

Clin Cancer Res. 2007 Mar 15;13(6):1789-93.

36.

Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses.

Weigel BJ, Panoskaltsis-Mortari A, Diers M, Garcia M, Lees C, Krieg AM, Chen W, Blazar BR.

Exp Hematol. 2006 Oct;34(10):1403-12.

PMID:
16982333
37.

Autologous stem cell transplantation for high-risk Ewing's sarcoma and other pediatric solid tumors.

Fraser CJ, Weigel BJ, Perentesis JP, Dusenbery KE, DeFor TE, Baker KS, Verneris MR.

Bone Marrow Transplant. 2006 Jan;37(2):175-81.

PMID:
16273111
38.

Aprepitant for the control of chemotherapy induced nausea and vomiting in adolescents.

Smith AR, Repka TL, Weigel BJ.

Pediatr Blood Cancer. 2005 Nov;45(6):857-60.

PMID:
15849684
39.

A novel system for simultaneous in vivo tracking and biological assessment of leukemia cells and ex vivo generated leukemia-reactive cytotoxic T cells.

Sauer MG, Ericson ME, Weigel BJ, Herron MJ, Panoskaltsis-Mortari A, Kren BT, Levine BL, Serody JS, June CH, Taylor PA, Blazar BR.

Cancer Res. 2004 Jun 1;64(11):3914-21.

40.

Osteosarcoma in the first decade of life.

Nagarajan R, Weigel BJ, Thompson RC, Perentesis JP.

Med Pediatr Oncol. 2003 Nov;41(5):480-3. No abstract available.

PMID:
14515397
41.
42.

The adjuvant effects of Mycobacterium tuberculosis heat shock protein 70 result from the rapid and prolonged activation of antigen-specific CD8+ T cells in vivo.

Harmala LA, Ingulli EG, Curtsinger JM, Lucido MM, Schmidt CS, Weigel BJ, Blazar BR, Mescher MF, Pennell CA.

J Immunol. 2002 Nov 15;169(10):5622-9.

43.

Comparative analysis of murine marrow-derived dendritic cells generated by Flt3L or GM-CSF/IL-4 and matured with immune stimulatory agents on the in vivo induction of antileukemia responses.

Weigel BJ, Nath N, Taylor PA, Panoskaltsis-Mortari A, Chen W, Krieg AM, Brasel K, Blazar BR.

Blood. 2002 Dec 1;100(12):4169-76. Epub 2002 Aug 8.

PMID:
12393694
44.

Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma.

Weigel BJ, Breitfeld PP, Hawkins D, Crist WM, Baker KS.

J Pediatr Hematol Oncol. 2001 Jun-Jul;23(5):272-6.

PMID:
11464981
45.
46.

Retinoblastoma and Hirschsprung disease in a patient with interstitial deletion of chromosome 13.

Weigel BJ, Pierpont ME, Young TL, Mutchler SB, Neglia JP.

Am J Med Genet. 1998 May 26;77(4):285-8. Review.

PMID:
9600737
47.
48.

Cloning and expression in Escherichia coli of isopenicillin N synthetase genes from Streptomyces lipmanii and Aspergillus nidulans.

Weigel BJ, Burgett SG, Chen VJ, Skatrud PL, Frolik CA, Queener SW, Ingolia TD.

J Bacteriol. 1988 Sep;170(9):3817-26.

Supplemental Content

Loading ...
Support Center